J&J-related uncertainties are behind us now
11/03/25 -"Yesterday, J&J announced it would not exercise its option to license HexaBody-CD38 (previously deemed to be Darzalex’s successor) from Genmab, thereby ending the uncertainty around this ..."
Pages
50
Language
English
Published on
11/03/25
You may also be interested by these reports :
28/10/25
The Q3 operating profitability was slightly behind the street’s expectations, though sales were in line with consensus. The quarterly performance was ...
24/10/25
The Q3 operating profitability came in considerably ahead of the street’s estimates, though sales met expectations. The performance was driven by ...
23/10/25
The Q3 sales missed expectations by a small margin; however, the management upgraded its 2025 earnings outlook. The Pharmaceuticals segment was again ...
23/10/25
Lonza’s strong Q3 commentary reaffirmed its commitment to meeting the 2025 guidance, boosting investor sentiment. While operational figures were not ...